Table 2.
Comparison of hepatic steatosis indices between statin users and non-users
| Statin users | Non-users | |||||
|---|---|---|---|---|---|---|
| S1 | S2 | DM-without-S | S1 | S2 | DM-without-S | |
| n = 9 | n = 9 | n = 44 | n = 2 | n = 6 | n = 56 | |
| Hepatic steatosis index (IQR) | 50.4 (6.5)* | 46.8 (5.5) | 42.4 (10.1) | 51.6 (N.A) | 44.6 (9.4) | 42.9 (10.6) |
|
Framingham steatosis index (IQR) |
1.12 (0.9)* | 0.72 (1.7) | 0.024 (1.9) | 1.5 (N.A.) | 0.15 (2.1) | −0.23 (1.9) |
S1: newly diagnosed patients with scleroedema out of 113 consecutive patients with diabetes mellitus (DM); S2: 15 patients with diabetes and scleroedema adultorum of Buschke treated in a tertiary care centre; DM-without-S: consecutive diabetes patients without scleroedema. *P < 0.05 values are for the comparisons of lipid parameters between patients with scleroedema and those with diabetes without scleroedema. Data are expressed as median (interquartile range, IQR). Mann Whitney U test was applied to calculate P-values